Review
. 1992 Apr;19(2 Suppl 5):59-62; discussion 62-3.
Bleomycin and tetracycline in malignant pleural effusions: a review
Affiliations
- PMID: 1384146
Item in Clipboard
Review
Bleomycin and tetracycline in malignant pleural effusions: a review
Semin Oncol.
1992 Apr.
Abstract
Pleural effusions remain a distressing and symptomatic problem in cancer patients. Once a malignant pleural effusion is diagnosed, appropriate therapy may provide symptomatic relief and improved quality of life. In this paper, we review previous data on chest tube drainage and pleurodesis in patients with malignant pleural effusions. A comparison is made of the various sclerosing agents. Specifically, recent data from a study comparing bleomycin and tetracycline as sclerosing agents are discussed. These data show a clear advantage with bleomycin at both 30-day and 90-day end points--30-day recurrence, 36% versus 67%; 90-day recurrence, 30% versus 53%.
Similar articles
-
Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions.J Thorac Cardiovasc Surg. 1993 Apr;105(4):743-7; discussion 747-8. J Thorac Cardiovasc Surg. 1993. PMID: 7682268 Clinical Trial.
-
Bleomycin "clearly superior" to tetracycline for malignant pleural effusions.Oncology (Williston Park). 1990 Sep;4(9):19. Oncology (Williston Park). 1990. PMID: 1698432 No abstract available.
-
On the management of malignant pleural effusions.Chest. 1994 Jan;105(1):1-2. doi: 10.1378/chest.105.1.1a. Chest. 1994. PMID: 7506134 No abstract available.
-
[Pleurodesis in malignant pleural effusion].Ned Tijdschr Geneeskd. 1997 Sep 20;141(38):1810-4. Ned Tijdschr Geneeskd. 1997. PMID: 9545735 Review. Dutch.
-
[Current treatment strategy in malignant pleural effusion].Wien Klin Wochenschr. 1996;108(9):255-61. Wien Klin Wochenschr. 1996. PMID: 8686317 Review. German.
Cited by
-
Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin.Ecancermedicalscience. 2014 Apr 25;8:424. doi: 10.3332/ecancer.2014.424. eCollection 2014. Ecancermedicalscience. 2014. PMID: 24834119 Free PMC article.
-
Management of malignant pleural effusions.Drugs. 1998 Jan;55(1):47-58. doi: 10.2165/00003495-199855010-00004. Drugs. 1998. PMID: 9463789 Review.
-
Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.BMC Palliat Care. 2004 Sep 9;3(1):4. doi: 10.1186/1472-684X-3-4. BMC Palliat Care. 2004. PMID: 15357871 Free PMC article.
-
Evaluation of Topical Sclerosant Agents for Minimization of Postmastectomy Seroma: A Placebo-Controlled, Double-Blind, Randomized Trial.Eur J Breast Health. 2023 Apr 1;19(2):134-139. doi: 10.4274/ejbh.galenos.2023.2022-11-1. eCollection 2023 Apr. Eur J Breast Health. 2023. PMID: 37025572 Free PMC article.
-
Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.World J Surg Oncol. 2004 May 20;2:16. doi: 10.1186/1477-7819-2-16. World J Surg Oncol. 2004. PMID: 15153245 Free PMC article.